Key Points
-
The selection of agents for cancer prevention requires a thorough understanding of the potential efficacy and toxicities that are associated with specific agents.
-
Evidence of effectiveness for prevention comes from a knowledge of mechanisms, in vitro and animal in vivo experimental data, epidemiological case–control and cohort studies, and data from clinical trials (both early-phase cancer prevention trials and secondary endpoint analysis of trials performed for other indications).
-
Risk–benefit considerations are crucial to the choice of agents for cancer prevention. The greater the risk of cancer, the greater the toxicity that is acceptable. There is a great need to improve risk-assessment tools to identify those individuals with the highest cancer risk who stand to gain the most benefit from preventive interventions.
-
Understanding the molecular mechanisms and the temporal sequence of events that result in carcinogenesis are crucial to the choice of agents and the design of prevention trials. Interventions need to target specific abnormalities when these abnormalities are crucial to cancer development.
-
New clinical trial designs are needed for efficient cancer preventive drug evaluation. Nesting 'prevention endpoints' into cancer treatment trials provides opportunities for the simultaneous development of agents for prevention and treatment if the toxicity profile of the agent is benign enough to warrant prevention applications.
Abstract
Given the lack of progress in curing metastatic epithelial cancers, there is intense interest in, and a sound scientific rationale for, pursuing strategies to prevent cancer. However, although several clinical trials have shown efficacy in cancer prevention, few have resulted in changes to medical practice, and some trials have even shown harm. Recent experiences with serious side effects identified in cancer prevention trials underscore the need to re-evaluate our approach to clinical chemopreventive drug development, and to establish a framework for agent selection for future trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Saccomanno, G. et al. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 33, 256–270 (1974).
Lippman, S. M., Benner, S. E. & Hong, W. K. Cancer chemoprevention. J. Clin. Oncol. 12, 851–873 (1994).
Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 190, 1371–1388 (1998). This article documents the effectiveness and side-effect profile of tamoxifen in reducing the incidence of breast cancer in high-risk women.
Giardiello, F. M. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313–1316 (1993).
Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946–1952 (2000). References 4 and 5 show the effectiveness of NSAIDs in regressing colorectal adenomas in the very high-risk familial adenomatous polyposis cohort.
The ATBC Study Group. The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330, 1029–1035 (1994).
Omenn, G. S. et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150–1155 (1996). References 6 and 7 show the increased lung cancer incidence in smokers treated with β-carotene in two large randomized placebo-controlled trials.
Vogel, V. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295, 2727–2741 (2006).
Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071–1080 (2005).
Greenwald, P. β-Carotene and lung cancer: a lesson for future chemoprevention investigations? J. Natl Cancer Inst. 95, E1–E7 (2003).
De Luca, L. M. & Ross, S. A. β-carotene increases lung cancer incidence in cigarette smokers. Nutrition Rev. 54, 178–180 (1996).
Meyskens, F. L. & Szabo, E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol. Biomarker Prev. 14, 1366–1369 (2005).
Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92–98 (2002).
The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351–360 (2004).
Wattenberg, L. W., Wiedmann, T. S. & Estensen, R. D. Chemoprevention of cancer of the upper respiratory tract of the Syrian Golder hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res. 64, 2347–2349 (2004).
Kato, H. et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350, 1713–1721 (2004).
Langer, C. J. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer 34, 297–303 (2001).
Cuzick, J. et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296–300 (2003).
Giardiello, F. M. et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 346, 1054–1059 (2002).
Sandler, R. S. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883–890 (2003).
Anderson, W. F., Umar, A. & Hawk, E. T. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin. Pharmacother. 4, 2193–2204 (2003).
Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879–1886 (1989).
Bach, P. B. et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst. 95, 470–478 (2003).
Silverman, S. Jr, Gorsky, M. & Lozada, F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53, 563–568 (1984).
Rosin, M. P. et al. Use of allelic loss to predict malignant risk for low grade epithelial dysplasia. Clin. Cancer Res. 6, 357–362 (2000). References 22, 23 and 25 show approaches to identifying individuals at high risk for cancer based primarily on demographic and historical variables (references 22, 23) or molecular abnormalities (reference 25).
Lam, S. et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in persons with dysplasia of the bronchial epithelium. Clin. Cancer Res. 10, 6502–6511 (2004).
American Cancer Society. Cancer Fact and FIGS 2006. American Cancer Society [online], (2006).
Haynes, R. B., Sackett, D. L., Taylor, D. W., Gibson, E. S. & Johnson, A. L. Increased absenteeism from work after detection and labeling of hypertensive patients. N. Engl. J. Med. 299, 741–744 (1978).
Cohen, M. H., Johnson, J. R. & Pazdur, R. U. S. Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) table ts from accelerated approval to full approval. Clin. Cancer Res. 11, 12–19 (2005).
Blanke, C. D. & Corless, C. L. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest. 23, 274–280 (2005).
Dy, G. K. et al. A phase II trial of imatinib (STI571)in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann. Oncol. 16, 1811–1816 (2005).
Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. & Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 60, 5040–5044 (2000).
Klein, E. A. et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol. Oncol. 21, 59–65 (2003).
Clark, L. C. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276, 1957–1963 (1996).
Kelloff, G. J. et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer (AACR Cancer Prevention Task Force). Clin. Cancer Res. 12, 3661–3697 (2006).
Dowsett, M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin. Cancer Res. 9, 502S–510S (2003).
Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J. Amer. Med. Assoc. 281, 2189–2197 (1999).
Hawk, E. T. and Levin, B. Colorectal cancer prevention. J. Clin. Oncol. 23, 378–391 (2005).
Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891–899 (2003).
Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E. & Hennekens, C. H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl Cancer Inst. 85, 1220–1224 (1993).
Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092–1102 (2005).
Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873–884 (2006).
Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885–895 (2006).
Peto, R., Doll, R., Buckley, J. D. & Sporn, M. B. Can Dietary beta-carotene materially reduce human cancer rates? Nature 290, 201–208 (1981).
Dorgan, J. F., Schatzkin, A. Antioxidant micronutrients in cancer prevention. Hematol. Oncol. Clin. North. Am. 5, 43–68 (1991).
Hennekens, C. et al. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 145–149 (1996).
Baron, J. A. et al. Neoplastic and antineoplastic effects of β-carotene on colorectal adenoma recurrence: results of a randomized trial. J. Natl Cancer Inst. 95, 717–722 (2003).
Acknowledgements
The author would like to thank R. Lubet for helpful discussions and comments.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
Related links
DATABASES
National Cancer Institute
Glossary
- Familial adenomatous polyposis
-
A genetic disorder that is characterized by an increased predisposition to colorectal cancer, associated with germ-line mutations of the APC gene.
- Hypertension
-
Persistently high arterial blood pressure. This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke and kidney disease.
- Case–control study
-
A study in which the risk factors of people with a disease are compared with those without the same disease.
- Cohort study
-
A clinical trial in which a cohort with a particular attribute (such as smokers or recipients of a drug) is followed prospectively and compared for some outcomes (such as cancer or cure) with another cohort not possessing the attribute.
- Pharmacodynamic
-
The effects on the biochemistry of the body that result from treatment with a drug or combination of drugs.
Rights and permissions
About this article
Cite this article
Szabo, E. Selecting targets for cancer prevention: where do we go from here?. Nat Rev Cancer 6, 867–874 (2006). https://doi.org/10.1038/nrc2008
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2008
This article is cited by
-
Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice
Scientific Reports (2015)
-
Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers
Nature Reviews Cancer (2009)
-
The tumour microenvironment as a target for chemoprevention
Nature Reviews Cancer (2007)
-
Are oncoantigens suitable targets for anti-tumour therapy?
Nature Reviews Cancer (2007)